{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:03:32Z","timestamp":1789664612104,"version":"4.0.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejmech.2025.117580","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T18:13:50Z","timestamp":1743358430000},"page":"117580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["2-(Phenylamino)-7,8-dihydroquinazolin-5(6H)-one, a promising scaffold for MAO-B inhibitors with potential GSK3\u03b2 targeting"],"prefix":"10.1016","volume":"291","author":[{"given":"Maria Luisa","family":"Di Paolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Salerno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Nordio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Piazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Sarno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Sarno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benito","family":"Natale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Poggetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Borreca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Baglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Barresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Da Settimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Cosconati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Taliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9828-9388","authenticated-orcid":false,"given":"Lisa","family":"Dalla Via","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117580_bib1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","article-title":"Ageing as a risk factor for neurodegenerative diseases","volume":"15","author":"Hou","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2025.117580_bib2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson's Disease","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117580_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2025.117580_bib4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.117580_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenensis of Parkinson's disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117580_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(23)01429-0","article-title":"Medical, surgical, and physical treatments for Parkinson's disease","volume":"403","author":"Foltynie","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117580_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pnpbp.2016.02.005","article-title":"Molecular aspects of monoamine oxidase B","volume":"69","author":"Ramsay","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejmech.2025.117580_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2025.117580_bib9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.14336\/AD.2020.1225","article-title":"An update on medical and surgical treatments of Parkinson's disease","volume":"12","author":"Nemade","year":"2021","journal-title":"Aging and Disease"},{"key":"10.1016\/j.ejmech.2025.117580_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41531-022-00277-z","article-title":"Safinamide in the treatment pathway of Parkinson's disease: a European delphi consensus","volume":"8","author":"Stocchi","year":"2022","journal-title":"npj Parkinsons Dis"},{"key":"10.1016\/j.ejmech.2025.117580_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jnc.13234","article-title":"The phosphorylation of \u03b1-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease","volume":"135","author":"Xu","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2025.117580_bib12","doi-asserted-by":"crossref","first-page":"9355","DOI":"10.3390\/ijms23169355","article-title":"The omnipresence of DYRK1A in human diseases","volume":"23","author":"Deboever","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117580_bib13","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1016\/j.neuron.2023.11.020","article-title":"Serine-129 phosphorylation of \u03b1-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function","volume":"111","author":"Parra-Rivas","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2025.117580_bib14","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214652120","article-title":"Phosphorylation of \u03b1-synuclein at T64 results in distinct oligomers and exerts toxicity in models of Parkinson's disease","volume":"120","author":"Matsui","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2025.117580_bib15","unstructured":"Alzheimer\u2019s Disease International. World Alzheimer Report 2022. Life after diagnosis: navigating treatment, care and support. https:\/\/alzheimer.ca\/sites\/default\/files\/documents\/World-Alzheimer-Report-2022_Alzheimer%27s-Disease-International.pdf."},{"key":"10.1016\/j.ejmech.2025.117580_bib16","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.117580_bib17","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033118","article-title":"Clinical neurology and epidemiology of the major neurodegenerative diseases","volume":"10","author":"Erkkinen","year":"2018","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejmech.2025.117580_bib18","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117580_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117580_bib20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117580_bib21","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1126\/science.298.5595.962","article-title":"The search for an amyloid solution","volume":"298","author":"Robinson","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117580_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2025.117580_bib23","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: current status and future directions","volume":"12","author":"Congdon","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2025.117580_bib24","first-page":"514","article-title":"The role of tau in Alzheimer's disease and related disorders, CNS neurosci","volume":"17","author":"Medeiros","year":"2011","journal-title":"Therapy"},{"key":"10.1016\/j.ejmech.2025.117580_bib25","doi-asserted-by":"crossref","first-page":"9098","DOI":"10.3390\/ijms22169098","article-title":"GSK-3\u03b2, FYN, and DYRK1A: master regulators in neurodegenerative pathways","volume":"22","author":"Demuro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117580_bib26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1742-4658.2010.07955.x","article-title":"The role of DYRK1A in neurodegenerative diseases","volume":"278","author":"Wegiel","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2025.117580_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2018.08.093","article-title":"DYRK1A kinase inhibition with emphasis on neurodegeneration: a comprehensive evolution story-cum-perspective","volume":"158","author":"Pathak","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib28","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.3390\/molecules26123724","article-title":"Role of monoamine oxidase activity in Alzheimer's disease: an insight into the therapeutic potential of inhibitors","volume":"26","author":"Behl","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117580_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/1673-5374.375299","article-title":"Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings","volume":"19","author":"Alborghetti","year":"2024","journal-title":"Neural. Regen. Res."},{"key":"10.1016\/j.ejmech.2025.117580_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-017-0279-1","article-title":"Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with \u03b3-secretase and regulates neuronal amyloid \u03b2-peptide levels","volume":"9","author":"Schedin-Weiss","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejmech.2025.117580_bib31","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/bph.13318","article-title":"Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and \u03b2-amyloid in ageing and Alzheimer's disease","volume":"173","author":"Weinreb","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117580_bib32","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00702-019-02082-0","article-title":"Selegiline: a molecule with innovative potential","volume":"127","author":"T\u00e1bi","year":"2020","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ejmech.2025.117580_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75204-8","article-title":"Critical assessment of anti-amyloid-\u03b2 monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness","volume":"14","author":"Avgerinos","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.117580_bib34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib35","doi-asserted-by":"crossref","first-page":"7640","DOI":"10.1021\/acs.jmedchem.8b00610","article-title":"Tau-centric multitarget approach for Alzheimer's disease: development of first-in-class dual glycogen synthase kinase 3\u03b2 and Tau-aggregation inhibitors","volume":"61","author":"Gandini","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113554","article-title":"Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3\u03b2\/DYRK1A dual inhibitors for the treatment of Alzheimer's disease","volume":"222","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116742","article-title":"Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease","volume":"61","author":"Kumar","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2270781","article-title":"Latest advances in dual inhibitors of acetylcholinesterase and monoaminoxidase B against Alzheimer's disease","volume":"38","author":"Zou","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib39","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ejmech.2018.02.015","article-title":"Novel indanone derivatives as MAO B\/H3R dual-targeting ligands for treatment of Parkinson's disease","volume":"148","author":"Affini","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib40","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1021\/acs.jmedchem.8b00204","article-title":"Docking screens for dual inhibitors of disparate drug targets for Parkinson's disease","volume":"61","author":"Jaiteh","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib41","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1021\/acschemneuro.0c00281","article-title":"Dual targeting of monomeric tau and \u03b1-synuclein aggregation: a new multitarget therapeutic strategy for neurodegeneration","volume":"11","author":"Gabr","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2025.117580_bib42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejmech.2015.08.027","article-title":"Investigation of new 2-aryl substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2","volume":"103","author":"Salerno","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib43","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ejmech.2018.03.013","article-title":"New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors","volume":"150","author":"Salerno","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/acsmedchemlett.8b00499","article-title":"Discovery of pyrido[3\u2019,2\u2019:5,6]thiopyrano[4,3-d]pyrimidine-based antiproliferative multikinase inhibitiors","volume":"10","author":"Salerno","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117580_bib45","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1016\/j.bmcl.2013.06.049","article-title":"Discovery, synthesis, and structure-activity relationships of 2-aminoquinazoline derivatives as a novel class of metabotropic glutamate receptor 5 negative allosteric modulators","volume":"23","author":"Kubas","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"61","key":"10.1016\/j.ejmech.2025.117580_bib46","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1021\/acs.jmedchem.8b00670","article-title":"4-Substituted benzenesulfonamides incorporating bi\/tricyclic moieties act as potent and isoform-selective carbonic anhydrase II\/IX inhibitors","volume":"61","author":"Salerno","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib47","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.bmc.2005.01.044","article-title":"Pyrazolopyridine antiherpetics: SAR of C2\u2032 and C7 amine substituents","volume":"13","author":"Johns","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bmc.2010.11.028","article-title":"Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues","volume":"19","author":"Manley-King","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib49","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1021\/jm070677y","article-title":"Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs","volume":"50","author":"Binda","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib50","first-page":"2651","volume":"vol. 56","author":"Pisani","year":"2013"},{"key":"10.1016\/j.ejmech.2025.117580_bib51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s004410100361","article-title":"Cellular localization of monoamine oxidase A and B in human tissues outside of the central nervous system","volume":"304","author":"Rodr\u00edguez","year":"2001","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.ejmech.2025.117580_bib52","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1016\/0006-2952(82)90575-5","article-title":"The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline","volume":"31","author":"Fowler","year":"1982","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117580_bib53","first-page":"428","article-title":"Reactive oxygen species production by monoamine oxidases in intact cells, Naunyn Schmiedebergs Arch","volume":"359","author":"Pizzinat","year":"1999","journal-title":"Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117580_bib54","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/ac9912247","article-title":"A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates","volume":"72","author":"Lloyd","year":"2000","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib55","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3390\/ph16081157","article-title":"The magic methyl and its tricks in drug discovery and development","volume":"16","author":"Pinheiro","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.117580_bib56","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1021\/jm101356p","article-title":"Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry","volume":"54","author":"Ishikawa","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib57","doi-asserted-by":"crossref","first-page":"12256","DOI":"10.1002\/anie.201303207","article-title":"Profound methyl effects in drug discovery and a call for new C-H methylation reactions","volume":"52","author":"Sch\u00f6nherr","year":"2013","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2025.117580_bib58","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1021\/jm001020e","article-title":"High-throughput permeability pH profile and high-throughput alkane\/water log P with artificial membranes","volume":"44","author":"Wohnsland","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib59","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijpharm.2016.01.074","article-title":"A new PAMPA model using an in-house brain lipid extract for screening the Blood\u2212Brain barrier permeability of drug candidates","volume":"501","author":"Bicker","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2025.117580_bib60","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5599\/admet.761","article-title":"Optimization of experimental conditions for skin-PAMPA measurements","volume":"8","author":"Soriano-Meseguer","year":"2020","journal-title":"ADMET DMPK"},{"key":"10.1016\/j.ejmech.2025.117580_bib61","doi-asserted-by":"crossref","first-page":"26105","DOI":"10.1002\/anie.202109464","article-title":"Inhibition of autophagy by a small molecule through covalent modification of the LC3 protein","volume":"60","author":"Shijie","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2025.117580_bib62","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1021\/jm00245a007","article-title":"Cardiovascular activity of aromatic guanidine compounds","volume":"18","author":"Hughes","year":"1975","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib63","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00018-011-0758-7","article-title":"Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A","volume":"69","author":"Sarno","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2025.117580_bib64","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.tiv.2013.12.006","article-title":"Inhibition of monoamine oxidase (MAO) by beta-carbolines and their interactions in live neuronal (PC12) and liver (HuH-7 and MH1C1) cells","volume":"28","author":"Santillo","year":"2014","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.ejmech.2025.117580_bib65","series-title":"Schr\u00f6dinger Release 2021-4: Protein Preparation Wizard","year":"2021"},{"key":"10.1016\/j.ejmech.2025.117580_bib66","series-title":"Schr\u00f6dinger Release 2021-4: Maestro","year":"2021"},{"key":"10.1016\/j.ejmech.2025.117580_bib67","series-title":"Schr\u00f6dinger Release 2021-4: LigPrep","year":"2021"},{"key":"10.1016\/j.ejmech.2025.117580_bib68","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: improving force field accuracy on challenging regimes of chemical space","volume":"17","author":"Lu","year":"2021","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2025.117580_bib69","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.117580_bib70","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J. Comput. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425003459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425003459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:40:59Z","timestamp":1778042459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425003459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":70,"alternative-id":["S0223523425003459"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117580","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2-(Phenylamino)-7,8-dihydroquinazolin-5(6H)-one, a promising scaffold for MAO-B inhibitors with potential GSK3\u03b2 targeting","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117580"}}